Article

Antagonism of purinergic signalling improves recovery from traumatic brain injury.

1 Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Brain (Impact Factor: 10.23). 01/2013; DOI: 10.1093/brain/aws286
Source: PubMed

ABSTRACT The recent public awareness of the incidence and possible long-term consequences of traumatic brain injury only heightens the need to develop effective approaches for treating this neurological disease. In this report, we identify a new therapeutic target for traumatic brain injury by studying the role of astrocytes, rather than neurons, after neurotrauma. We use in vivo multiphoton imaging and show that mechanical forces during trauma trigger intercellular calcium waves throughout the astrocytes, and these waves are mediated by purinergic signalling. Subsequent in vitro screening shows that astrocyte signalling through the 'mechanical penumbra' affects the activity of neural circuits distant from the injury epicentre, and a reduction in the intercellular calcium waves within astrocytes restores neural activity after injury. In turn, the targeting of different purinergic receptor populations leads to a reduction in hippocampal cell death in mechanically injured organotypic slice cultures. Finally, the most promising therapeutic candidate from our in vitro screen (MRS 2179, a P2Y1 receptor antagonist) also improves histological and cognitive outcomes in a preclinical model of traumatic brain injury. This work shows the potential of studying astrocyte signalling after trauma to yield new and effective therapeutic targets for treating traumatic brain injury.

1 Follower
 · 
130 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: For decades, studies have been focusing on the neuronal abnormalities that accompany neurodegenerative disorders. Yet, glial cells are emerging as important players in numerous neurological diseases. Because reactive astrocytes are associated with a variety of central nervous system (CNS) disorders, interest in the glial contribution to neuronal injury is exponentially increasing. Astrocytes, the main type of glia in the CNS, form extensive networks that physically and functionally connect neuronal synapses with cerebral blood vessels. Normal brain functioning strictly depends on highly specialized cellular cross-talk between these different partners to which Ca(2+), as a signaling ion, largely contributes. Altered intracellular Ca(2+) levels are associated with neurodegenerative processes/diseases and play a crucial role in the glial responses to injury. Most importantly, intracellular Ca(2+) increases in single astrocytes can be propagated toward neighboring cells as intercellular Ca(2+) waves, thereby recruiting a larger group of cells. The propagation of intercellular Ca(2+) waves largely depends on two, parallel, connexin (Cx) channel-based mechanisms: i) the diffusion of inositol 1,4,5-trisphosphate through gap junction channels that directly connect the cytoplasm of neighboring cells, and ii) the release of paracrine messengers such as glutamate and ATP through hemichannels ('half of a gap junction channel'). This review gives an overview of the current knowledge on Cx-mediated Ca(2+) communication among astrocytes as well as between astrocytes and other brain cell types in physiology and pathology, with a focus on the processes of neurodegeneration and reactive gliosis. Research on Cx-mediated astroglial Ca(2+) communication may ultimately shed light on the development of targeted therapies for neurodegenerative disorders in which astrocytes participate. This article is part of a Special Issue entitled: Calcium signaling in health and disease.
    Biochimica et Biophysica Acta 04/2014; 1843(10). DOI:10.1016/j.bbamcr.2014.04.016 · 4.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alterations in the activity of neural circuits are a common consequence of traumatic brain injury (TBI), but the relationship between single-neuron properties and the aggregate network behavior is not well understood. We recently reported that the GluN2B-containing NMDA receptors (NMDARs) are key in mediating mechanical forces during TBI, and that TBI produces a complex change in the functional connectivity of neuronal networks. Here, we evaluated whether cell-to-cell heterogeneity in the connectivity and aggregate contribution of GluN2B receptors to [Ca(2+)]i before injury influenced the functional rewiring, spontaneous activity, and network plasticity following injury using primary rat cortical dissociated neurons. We found that the functional connectivity of a neuron to its neighbors, combined with the relative influx of calcium through distinct NMDAR subtypes, together contributed to the individual neuronal response to trauma. Specifically, individual neurons whose [Ca(2+)]i oscillations were largely due to GluN2B NMDAR activation lost many of their functional targets 1 h following injury. In comparison, neurons with large GluN2A contribution or neurons with high functional connectivity both independently protected against injury-induced loss in connectivity. Mechanistically, we found that traumatic injury resulted in increased uncorrelated network activity, an effect linked to reduction of the voltage-sensitive Mg(2+) block of GluN2B-containing NMDARs. This uncorrelated activation of GluN2B subtypes after injury significantly limited the potential for network remodeling in response to a plasticity stimulus. Together, our data suggest that two single-cell characteristics, the aggregate contribution of NMDAR subtypes and the number of functional connections, influence network structure following traumatic injury.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 03/2014; 34(12):4200-13. DOI:10.1523/JNEUROSCI.4172-13.2014 · 6.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Brain inflammation is a common occurrence following responses to varied insults such as bacterial infections, stroke, traumatic brain injury and neurodegenerative disorders. A common mediator for these varied inflammatory responses is prostaglandin E 2 (PGE 2), produced by the enzymatic activity of cyclooxygenases (COX) 1 and 2. Previous attempts to reduce neuronal inflammation through COX inhibition, by use of nonsteroidal anti-inflammatory drugs (NSAIDs), have met with limited success. We are proposing the two-hit model for neuronal injury—an initial localized inflammation mediated by PGE 2 (first hit) and the simultaneous release of adenosine triphosphate (ATP) by injured cells (second hit), which significantly enhances the inflammatory response through increased synthesis of PGE 2 . Several evidences on the role of exogenous ATP in inflammation have been reported, including contrary instances where extracellular ATP reduces inflammatory events. In this review, we will examine the current literature on the role of P2 receptors, to which ATP binds, in modulating inflammatory reactions during neurodegeneration. Targeting the P2 receptors, therefore, provides a therapeutic alternative to reduce inflammation in the brain. P2 receptor-based anti-inflammatory drugs (PBAIDs) will retain the activities of essential COX enzymes, yet will significantly reduce neuroinflammation by decreasing the enhanced production of PGE 2 by extracellular ATP. INFLAMMATION WITHIN THE BRAIN Various environmental factors can lead to inflammation within the brain. These range from bacterial infections that cause acute inflammation to neurodegenerative disorders that mediate chronic inflammation. The inflammation may be restricted to a local region in focal ischemia or occur in a wider zone during traumatic brain injury. Inflammation could also result from an autoimmune response such as multiple sclerosis or in response to toxins and nerve agents (for general reviews, see Lucas et al., 2006; Aguzzi et al., 2013). Recent reports implicate inflammation con-tributing to the pathology of psychiatric disorders such as stress, depression and schizophrenia (Najjar et al., 2013), in metabolic syndromes such as obesity and type 2 diabetes (Purkayastha and Cai, 2013), and even as a response to increased neuronal activity (Xanthos and Sandkuhler, 2014). Irrespective of the type of inflammation, the molecular mediators are oftentimes the same –prostaglandin E 2 (PGE 2) or cytokines such as interleukin-1β Abbreviations: AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; ATP, adenosine triphosphate; COX, cyclooxygenase; IL-1β, interleukin-1β; IRF8, interferon regulatory factor 8; LPS, lipopolysaccharide; MCP1, mono-cyte chemotactic protein 1; MMP-9, matrix metalloproteinase 9; NSAIDs, non-steroidal anti-inflammatory drugs; PARP, poly (ADP-ribose) polymerase; PBAIDs, P2 receptor-based anti-inflammatory drugs; PGE 2 , prostaglandin E 2 ; PD, Parkinson's disease; TNF-α, tumor necrosis factor α; UTP, uridine triphosphate.
    Frontiers in Cellular Neuroscience 09/2014; 8:260. DOI:10.3389/fncel.2014.00260 · 4.18 Impact Factor

Full-text

Download
87 Downloads
Available from
May 19, 2014